3D Imaging Drug Design and Development LLC
3D Imaging Drug Design and Development LLC (United States) holds 13 active US FDA Type II Drug Master Files and 2 inactive and has DMF or CEP filings on record for 2 active ingredients. 12 FDA enforcement records are linked to it.
Sources: FDA Drug Master File list, EDQM certification database, FDA establishment registrations and enforcement records. How we read these records
Cite as: PharmaTek, “3D Imaging Drug Design and Development LLC: DMF, site and FDA enforcement record”, record as of 16 Nov 2026, pharmatek.co.uk/directory/3d-imaging-drug-design-and-development-llc
Overview
3D Imaging Drug Design and Development LLC is a private biopharmaceutical company that utilizes advanced 3D imaging technology to revolutionize drug design and development. The company is dedicated to improving therapeutic outcomes through innovative research and development processes.
Core services & business areas
Therapeutic areas
Active ingredients with DMF or CEP filings
Substances for which 3D Imaging Drug Design and Development LLC holds, or has held, a US FDA Drug Master File or an EU CEP. A filing is not proof of current supply. Open any ingredient to see all its holders, CAS number and product patent dates.
API / Drug Master Files
3D Imaging Drug Design and Development LLC holds 13 active (15 total) FDA Type II Drug Master Files. A Type II DMF is filed with the FDA to support an active ingredient in drug applications; an active filing can be referenced but is not proof of current supply, and inactive filings are historical.
- "89ZR-LINTUZUMAB INJECTIONActive2026-04-28
- Zr89-YS5Active2024-10-01
- I-124 HJAA-F11Active2024-09-17
- ZR89 OXINEActive2021-08-09
- 89 ZR-DARATUMUMABActive2020-12-31
- (F-18) CLOFARABINEActive2020-10-06
- 89ZR-DINUTUXIMABActive2020-07-29
- ZIRCONIUM-89 OXALATEActive2017-02-22
- I-124-MIBG INJECTIONActive2014-10-27
- DPA-713 I 124 INJECTIONActive2013-10-01
- FLUOROMISONIDAZOLE F 18 INJECTIONActive2013-07-19
- SODIUM IODIDE I 124Active2012-03-23
- [I-124] FIAU (FIALURIDINE)Active2010-07-23
- [I-124]CLR1404 INJECTIONInactive2013-12-27
- [F-18] FDPNInactive2010-09-15
FDA compliance signals
12 FDA enforcement records linked to this company.
- warning_letter2025-12-04
FDA Warning Letter (drug product)
- 4832024-01-31
Failure to develop written procedures
- 4832017-04-20
Testing Procedures- Conformance to Standards
- 4832017-04-20
Determination need for investigation
- 4832017-04-20
Written QA procedures established, followed
- 4832017-04-20
Adequate controls (general)
- 4832017-04-20
Use of reliable suppliers
- 4832017-04-20
Prevention of contamination
- 4832017-04-20
Failure to develop written procedures
- 4832017-04-20
Equipment not clean
- 4832017-04-20
Master Production and Control Records
- 4832017-04-20
Lab written procedures
Is this 3D Imaging Drug Design and Development LLC?
Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.
Need suppliers found and checked?
The Sourcing Desk turns these records into a checked shortlist: current filings, site, grade and regulatory history confirmed for your product, for a buyer-paid fixed fee and no supplier commission.